Showing results (61-70 of 101) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMAF Mandelli, M C Petti, A Ardia, et al.
British Journal of Haematology|September 1, 1995
Interleukin-3 priming in acute myeloid leukaemia patientsA Tafuri, L de Felice, A Goodacre, et al.
Lancet (London, England)|December 12, 1992
Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemiaF Lo Coco, D Diverio, P P Pandolfi, et al.
British Journal of Haematology|May 1, 1990
Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patientsG Visani, C Finelli, U Castelli, et al.
Haematologica|March 1, 1993
Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim reportM A Aloe Spiriti, M C Petti, R Latagliata, et al.
Blood|April 15, 1991
Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemiaF Lo Coco, G Avvisati, D Diverio, et al.
Cancer Research|August 15, 1993
Southern blot analysis of ALL-1 rearrangements at chromosome 11q23 in acute leukemiaF Lo Coco, F Mandelli, M Breccia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998
The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 yearsR Latagliata, G Avvisati, F Lo Coco, et al.
Leukemia & Lymphoma|April 28, 2000
Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs inductionR Latagliata, M Breccia, A Pulsoni, et al.
Leukemia & Lymphoma|January 1, 1993
Is recombinant human erythropoietin treatment in myelodysplastic syndromes worthwhile?M A Aloe Spiriti, M C Petti, R Latagliata, et al.
Pageof 11